Serotonin (5-Hydroxytryptamine, 5-HT)

Introduction

Serotonin (5 Hydroxytryptamine, 5 Ht) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Introduction

Serotonin (5 Hydroxytryptamine, 5 Ht) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Serotonin, also known as 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter derived from the amino acid tryptophan that modulates a vast array of physiological and behavioral processes, including mood, cognition, sleep, appetite, pain perception, and neuroendocrine function. In the central nervous system, serotonergic [neurons](/entities/neurons) are concentrated in the raphe nuclei of the brainstem, from which they project diffusely throughout the brain, including the [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), [basal-ganglia](/brain-regions/basal-ganglia), [thalamus](/brain-regions/thalamus), and [cerebellum](/brain-regions/cerebellum) [@lanciego2025]. [@zhang2025]

Serotonergic dysfunction is a prominent feature of multiple [neurodegenerative diseases. In [alzheimers](/diseases/alzheimers-disease), early degeneration of the raphe nuclei and depletion of serotonin contribute to depression, sleep disturbances, circadian disruption, and cognitive decline. In [parkinsons](/diseases/parkinsons-disease), serotonergic pathology is implicated in non-motor symptoms including depression, anxiety, psychosis, and levodopa-induced dyskinesias. Emerging evidence positions the serotonergic system as a promising therapeutic target across neurodegenerative conditions [@zhang2025]. [@meltzer1998]

Synthesis and Metabolism

Biosynthetic Pathway

Serotonin is synthesized from the essential amino acid L-tryptophan through a two-step enzymatic process: [@ohno2011]

Notably, serotonin does not cross the [blood-brain-barrier](/entities/blood-brain-barrier), so CNS and peripheral serotonin pools are functionally independent. Approximately 95% of total body serotonin resides in the gastrointestinal tract, where it is produced by enterochromaffin cells—a connection highly relevant to [gut-brain-axis](/entities/gut-brain-axis) signaling in neurodegeneration. [@barnes2007]

Vesicular Transport and Release

After synthesis, serotonin is transported into synaptic vesicles by vesicular monoamine transporter 2 (VMAT2/SLC18A2). Upon neuronal depolarization, 5-HT is released into the synaptic cleft by calcium-dependent exocytosis. [@codony2011]

Reuptake and Degradation

Serotonin signaling is terminated primarily by the serotonin transporter (SERT/SLC6A4), which mediates reuptake of 5-HT from the synaptic cleft into the presynaptic terminal. SERT is the principal target of selective serotonin reuptake inhibitors (SSRIs), the most widely prescribed class of antidepressants. [@chowdhury2024]

Intracellular serotonin is degraded by monoamine oxidase A (MAO-A) to 5-hydroxyindoleacetaldehyde, which is further oxidized by aldehyde dehydrogenase to 5-hydroxyindoleacetic acid (5-HIAA), the primary serotonin metabolite. 5-HIAA levels in cerebrospinal fluid (CSF) serve as a biomarker of central serotonergic activity and are consistently reduced in [alzheimers](/diseases/alzheimers-disease) patients [@meltzer1998]. [@li2024]

Melatonin Pathway

In the pineal gland, serotonin serves as the precursor for melatonin synthesis through sequential N-acetylation (by AANAT) and O-methylation (by ASMT). This serotonin-melatonin pathway is critical for circadian rhythm regulation and is severely disrupted in AD, contributing to sundowning behavior and sleep-wake cycle disturbances. [@carta2017]

Serotonin Receptors

The serotonin receptor system is the most complex of any neurotransmitter, comprising 7 families (5-HT1 to 5-HT7) and at least 14 receptor subtypes. All are G protein-coupled receptors except 5-HT3, which is a ligand-gated ion channel. [@duan2024]

5-HT1 Family (Gi/Go-coupled, inhibitory)

• 5-HT1A: Expressed as somatodendritic autoreceptors on raphe [neurons](/entities/neurons) (inhibiting serotonin release) and as postsynaptic receptors in [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), and amygdala. 5-HT1A receptor density is reduced in AD brains, correlating with cognitive decline and neurofibrillary tangle burden. 5-HT1A agonists (buspirone, tandospirone) show potential for treating behavioral symptoms in AD and motor complications in PD [@ohno2011].
• 5-HT1B/1D: Primarily presynaptic autoreceptors/heteroreceptors regulating neurotransmitter release. Targets of triptan antimigraine drugs.

5-HT2 Family (Gq-coupled, excitatory)

• 5-HT2A: Highly expressed in cortical pyramidal [neurons](/entities/neurons); mediates psychedelic effects and is the target of atypical antipsychotics (risperidone, quetiapine). 5-HT2A receptor density is reduced in AD temporal and frontal [cortex](/brain-regions/cortex). Pimavanserin, a selective 5-HT2A inverse agonist, is approved for [parkinsons](/diseases/parkinsons-disease) psychosis and is being investigated for AD psychosis [@barnes2007].
• 5-HT2C: Expressed in the choroid plexus and limbic structures; regulates appetite, mood, and CSF production. Relevant to weight changes in neurodegenerative disease.

5-HT3 (Ligand-gated cation channel)

The only ionotropic serotonin receptor; mediates fast excitatory neurotransmission. Expressed on GABAergic interneurons and vagus nerve afferents. 5-HT3 antagonists (ondansetron) have shown modest procognitive effects in preclinical AD models. [@rodrguez2012]

5-HT4 (Gs-coupled, excitatory)

Expressed in [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), and gastrointestinal tract. 5-HT4 receptor activation promotes non-amyloidogenic processing of [app](/genes/app) [@politis2015]

Expressed exclusively in the CNS, primarily in striatum, [hippocampus](/brain-regions/hippocampus), and [cortex](/brain-regions/cortex). 5-HT6 receptor antagonists (idalopirdine, intepirdine) enhance [acetylcholine](/entities/acetylcholine), [glutamate](/entities/glutamate), and [dopamine](/entities/dopamine) release and have been extensively investigated as cognitive enhancers in AD. Despite promising preclinical data, Phase III clinical trials have not met primary endpoints, though the pharmacological rationale remains sound [@codony2011]. [@dopamine]

5-HT7 (Gs-coupled, excitatory)

Involved in circadian rhythm regulation, thermoregulation, and memory. Expressed in [hippocampus](/brain-regions/hippocampus), [thalamus](/brain-regions/thalamus), and hypothalamus. 5-HT7 receptor modulation may address circadian disturbances in AD. [@norepinephrine]

Role in Neurodegenerative Diseases

Alzheimer's Disease

Serotonergic dysfunction is a consistent finding in AD, with multiple lines of evidence: [@acetylcholine]

• Psychosis: 5-HT2A receptor upregulation in [cortex](/brain-regions/cortex) contributes to visual hallucinations; pimavanserin targets this mechanism.
• Sleep Disturbances: REM sleep behavior disorder and excessive daytime sleepiness linked to raphe nuclei degeneration.
• Cognitive Decline: Serotonergic denervation contributes to executive dysfunction and dementia in PD.

Amyotrophic Lateral Sclerosis

Emerging evidence links serotonergic dysfunction to [als](/diseases/amyotrophic-lateral-sclerosis): [@neurotransmitters]

• Reduced 5-HT levels in the spinal cord of ALS patients
• Serotonergic modulation of motor neuron excitability
• 5-HT2B/2C receptor involvement in spasticity
• Potential role in pseudobulbar affect (pathological crying/laughing)

Frontotemporal Dementia

[ftd](/diseases/frontotemporal-dementia) patients show serotonergic deficits contributing to behavioral disinhibition, apathy, dietary changes, and compulsive behaviors. SSRI treatment is first-line pharmacotherapy for behavioral symptoms of FTD. [@parkinsons]

Therapeutic Approaches

Current Serotonergic Therapies in Neurodegeneration

• SSRIs (escitalopram, citalopram, fluoxetine, sertraline): First-line for depression in AD and PD; citalopram has shown modest efficacy for agitation in AD (CitAD trial). SSRIs also reduce [amyloid-beta](/proteins/amyloid-beta) production in preclinical models [@zhang2025].
• Pimavanserin (Nuplazid): Selective 5-HT2A inverse agonist approved for PD psychosis; under investigation for AD psychosis.
• Trazodone: 5-HT2A antagonist and serotonin reuptake inhibitor; used for insomnia and agitation in dementia.
• Buspirone: 5-HT1A partial agonist used for anxiety in dementia patients.

Emerging Strategies

Serotonin as a Biomarker

• CSF 5-HIAA: Reduced in AD and PD; correlates with severity of depressive symptoms and cognitive impairment
• SERT PET imaging: 11CDASB PET reveals serotonergic denervation patterns in AD and PD, predicting depression and cognitive decline
• Platelet serotonin: Peripheral serotonin in platelets (which express SERT) mirrors central serotonergic function; reduced in AD patients
• Tryptophan metabolomics: Altered kynurenine/tryptophan ratio in AD reflects immune-mediated diversion of tryptophan away from serotonin synthesis toward neurotoxic kynurenine metabolites

Background

The study of Serotonin (5 Hydroxytryptamine, 5 Ht) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@alzheimers]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@serotonin]

Brain Atlas Resources

• Allen Human Brain Atlas: [Serotonin expression search](https://human.brain-map.org/microarray/search/show?search_term=Serotonin)
• Allen Mouse Brain Atlas: [Serotonin search](https://mouse.brain-map.org/search/index.html?query=Serotonin)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [Serotonin developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Serotonin)
• [Serotonergic [Neurons](/entities/neurons)[/[serotonergic-neurons
• [Serotonin Receptors
• [Depression](/diseases/depression)
• [Neurotransmitter](/genes/ran)
• [Raphe Nuclei](/brain-regions/raphe-nuclei)
• [Mood Disorders

External Links

• [PubMed Search: Serotonin (5-Hydroxytryptamine, 5-HT)](https://pubmed.ncbi.nlm.nih.gov/?term=Serotonin+%285-Hydroxytryptamine%2C+5-HT%29)
• [Google Scholar Search: Serotonin (5-Hydroxytryptamine, 5-HT)](https://scholar.google.com/scholar?q=Serotonin+%285-Hydroxytryptamine%2C+5-HT%29)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Serotonin (5-Hydroxytryptamine, 5-HT) discovered through SciDEX knowledge graph analysis: